Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Taking a statin medication is an effective, safe, and low-cost way to lower cholesterol and reduce risk of cardiovascular events. Despite clinicians recommending that many patients with diabetes take ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Digital physical therapy company Hinge Health went public last week, raising $437 million and ending an IPO drought for ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival Novo ...

Keynotes from Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva will showcase how connected platforms and AI can streamline the development of new medicines BARCELONA, May 27, 2025 /PRNewswire/ ...

Keynotes from Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva will showcase how connected platforms and AI can streamline the development of new medicines ...